Celsion Corporation (CLSN)
Россия
  • Россия
  • Украина

Celsion Corporation (CLSN)

Contact Details

997 Lenox Dr Ste 100, Lawrenceville, New Jersey, USA 08648-2317
(609) 896-9100
997 Lenox Dr Ste 100, Lawrenceville, New Jersey, USA 08648-2317

General Information

Celsion is dedicated to the development and commercialization of oncology drugs including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery systems. Celsion has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Long Island Jewish Health System.

Contact Information

Phone(609) 896-9100
Website 1http://www.celsion.com
LinkedInLinkedIn
Thomson Reuters PermID4295912038

Executives

NamePositionTotal Annual CompensationYearPercent Change in Compensation
CEO, Chairman of the Board and President$1,694,787201477.4%
Chief Medical Officer and Vice President$824,966201469.3%
Chief Scientific Officer and Executive VP$479,3482014
Divisional Senior VP$805,543201483.0%

Corporate Data

Industries

  • Pharmaceutical Preparation Manufacturing

SIC Industries

  • Pharmaceutical Preparations

Company Size

Sales Volume$500,000
Employees25

Ownership

Ticker SymbolCLSN
ExchangeNASDAQ (NAS)
Year Founded1982

Stocks

Previous Close1.48
Open1.51
Bid1.52 x 400
Ask1.53 x 3,500
Day`s Range1.49 - 1.55
52-Week Range1.08 - 3.15
Average Volume (1M)52,140
Beta2.22x
Market Cap.$34.67 Million
Last Dividend Amount0
1y Target Price Est.8.63

Pre-IPO

Summary of Form-D Filings

    Filing History

  • Celsion Corp has filed 2 Form Ds since 2008. Of these filings, 2 have been for unique offerings.
  • Through these filings, they have raised $13,570,000, and reported $0 remaining.
  • They have paid finder`s fees totaling 561,750.
  • They have not used any of the proceeds from its offerings to pay officers or directors.
  • The types of securities they have issued are Equity, Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security, and other securities.
  • They have relied on the following exemptions in past filings Rule 506(b).

    Analysis of Past Filings

  • Celsion Corp has filed about as many filings as an average company in the Pharmaceuticals category.
  • They have had 1 more unique offering compared to an average company in the Pharmaceuticals category.
  • The total amount raised they have raised is 356% higher than the average for a company in the Pharmaceuticals category.
  • They have paid 4.1397% in finder`s fees, which is 0.95% more than other companies than the average for a company in the Pharmaceuticals category.
  • They have paid in sales commissions, which is than the average for a company in the Pharmaceuticals category.

Form-D Filings

Filing DateFiling TypeTotal Offering AmountTotal Amount RaisedTotal Remaining For Sale
June 08, 2015New$5,070,000$5,070,000$0
June 24, 2014New$8,500,000$8,500,000$0

Financials

Period EndingDec. 31, 2015Sep. 30, 2015Jun. 30, 2015Mar. 31, 2015
Total Revenue125125125125
Cost of Revenue----
Gross Profit125125125125
Research Development3,702.42,883.53,567.74,506.4
Selling General and Administrative1,369.51,483.71,801.82,031.8
Depreciation and Amortization----
Other Operating Expenses-(0.1)--
Total Operating Expenses5,071.94,367.15,369.56,538.2
Other Income/Expenses Net----
Earnings Before Interest and Taxes(4,946.9)(4,242.1)(5,244.5)(6,413.2)
Interest Expense281.9322.7360.3392.3
Income Before Tax(5,513.9)(4,267.4)(5,674.7)(7,005.1)
Income Tax Expense----
Minority Interest----
Net Income from Continuing Ops(5,513.9)(4,267.4)(5,674.7)(7,005.1)
Discontinued Operations----
Extraordinary Items----
Effect of Accounting Changes----
Other Items----
Net Income(5,513.9)(4,267.4)(5,674.7)(7,005.1)
Preferred Stock and Other Adjustments----
Net Income Applicable to Common Shares(5,513.9)(4,267.4)(5,674.7)(7,005.1)